Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia
One of the key features of acute myeloid leukemia (AML), a group of very aggressive myeloid malignancies, is their strikingly heterogenous outcomes. Accurate biomarkers are needed to improve prognostic assessment. Glutamate oxaloacetate transaminase 1 (GOT1) is essential for cell proliferation and a...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00379/full |
id |
doaj-e606f2c3102b46b789ea2ac4ae2f15ea |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhiheng Cheng Zhiheng Cheng Zhiheng Cheng Yifeng Dai Tiansheng Zeng Yan Liu Longzhen Cui Tingting Qian Tingting Qian Chaozeng Si Wenhui Huang Wenhui Huang Ying Pang Xu Ye Jinlong Shi Lin Fu Lin Fu Lin Fu |
spellingShingle |
Zhiheng Cheng Zhiheng Cheng Zhiheng Cheng Yifeng Dai Tiansheng Zeng Yan Liu Longzhen Cui Tingting Qian Tingting Qian Chaozeng Si Wenhui Huang Wenhui Huang Ying Pang Xu Ye Jinlong Shi Lin Fu Lin Fu Lin Fu Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia Frontiers in Oncology acute myeloid leukemia glutamate oxaloacetate transaminase 1 chemotherapy allogeneic hematopoietic stem cell transplantation prognosis |
author_facet |
Zhiheng Cheng Zhiheng Cheng Zhiheng Cheng Yifeng Dai Tiansheng Zeng Yan Liu Longzhen Cui Tingting Qian Tingting Qian Chaozeng Si Wenhui Huang Wenhui Huang Ying Pang Xu Ye Jinlong Shi Lin Fu Lin Fu Lin Fu |
author_sort |
Zhiheng Cheng |
title |
Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia |
title_short |
Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia |
title_full |
Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia |
title_fullStr |
Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia |
title_full_unstemmed |
Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid Leukemia |
title_sort |
upregulation of glutamic-oxaloacetic transaminase 1 predicts poor prognosis in acute myeloid leukemia |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2020-03-01 |
description |
One of the key features of acute myeloid leukemia (AML), a group of very aggressive myeloid malignancies, is their strikingly heterogenous outcomes. Accurate biomarkers are needed to improve prognostic assessment. Glutamate oxaloacetate transaminase 1 (GOT1) is essential for cell proliferation and apoptosis by regulating cell's metabolic dependency on glucose. It is unclear whether the expression level of GOT1 has clinical implications in AML. Therefore, we analyzed the data of 155 AML patients with GOT1 expression information from The Cancer Genome Atlas (TCGA) database. Among them, 84 patients were treated with chemotherapy alone, while 71 received allogeneic hematopoietic stem cell transplantation (allo-HSCT). In both treatment groups, high GOT1 expression was associated with shorter event-free survival (EFS) and overall survival (OS) (all P < 0.05). Multivariate analysis identified several independent risk factors for both EFS and OS in the chemotherapy-only group, including high GOT1 expression, age ≥60 years, white blood cell count ≥15 × 109/L, bone marrow blasts ≥70%, and DNMT3A, RUNX1 or TP53 mutations (all P < 0.05); but in the allo-HSCT group, the only independent risk factor for survival was high GOT1 expression (P < 0.05 for both EFS and OS). Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that the genes related to GOT1 expression were mainly concentrated in “hematopoietic cell lineage” and “leukocyte transendothelial migration” signaling pathways. Collectively, GOT1 expression may be a useful prognostic indicator in AML, especially in patients who have undergone allo-HSCT. |
topic |
acute myeloid leukemia glutamate oxaloacetate transaminase 1 chemotherapy allogeneic hematopoietic stem cell transplantation prognosis |
url |
https://www.frontiersin.org/article/10.3389/fonc.2020.00379/full |
work_keys_str_mv |
AT zhihengcheng upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT zhihengcheng upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT zhihengcheng upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT yifengdai upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT tianshengzeng upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT yanliu upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT longzhencui upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT tingtingqian upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT tingtingqian upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT chaozengsi upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT wenhuihuang upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT wenhuihuang upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT yingpang upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT xuye upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT jinlongshi upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT linfu upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT linfu upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia AT linfu upregulationofglutamicoxaloacetictransaminase1predictspoorprognosisinacutemyeloidleukemia |
_version_ |
1725040404491927552 |
spelling |
doaj-e606f2c3102b46b789ea2ac4ae2f15ea2020-11-25T01:41:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-03-011010.3389/fonc.2020.00379484907Upregulation of Glutamic-Oxaloacetic Transaminase 1 Predicts Poor Prognosis in Acute Myeloid LeukemiaZhiheng Cheng0Zhiheng Cheng1Zhiheng Cheng2Yifeng Dai3Tiansheng Zeng4Yan Liu5Longzhen Cui6Tingting Qian7Tingting Qian8Chaozeng Si9Wenhui Huang10Wenhui Huang11Ying Pang12Xu Ye13Jinlong Shi14Lin Fu15Lin Fu16Lin Fu17Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsTranslational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsDepartment of Biomedical Sciences, University of Sassari, Sassari, ItalyTranslational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, ChinaTranslational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, ChinaDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaTranslational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Operations and Information Management, China-Japan Friendship Hospital, Beijing, ChinaDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaTranslational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Biomedical Engineering, Chinese PLA General Hospital, Beijing, ChinaDepartment of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaTranslational Medicine Center, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Hematology, Huaihe Hospital of Henan University, Kaifeng, ChinaOne of the key features of acute myeloid leukemia (AML), a group of very aggressive myeloid malignancies, is their strikingly heterogenous outcomes. Accurate biomarkers are needed to improve prognostic assessment. Glutamate oxaloacetate transaminase 1 (GOT1) is essential for cell proliferation and apoptosis by regulating cell's metabolic dependency on glucose. It is unclear whether the expression level of GOT1 has clinical implications in AML. Therefore, we analyzed the data of 155 AML patients with GOT1 expression information from The Cancer Genome Atlas (TCGA) database. Among them, 84 patients were treated with chemotherapy alone, while 71 received allogeneic hematopoietic stem cell transplantation (allo-HSCT). In both treatment groups, high GOT1 expression was associated with shorter event-free survival (EFS) and overall survival (OS) (all P < 0.05). Multivariate analysis identified several independent risk factors for both EFS and OS in the chemotherapy-only group, including high GOT1 expression, age ≥60 years, white blood cell count ≥15 × 109/L, bone marrow blasts ≥70%, and DNMT3A, RUNX1 or TP53 mutations (all P < 0.05); but in the allo-HSCT group, the only independent risk factor for survival was high GOT1 expression (P < 0.05 for both EFS and OS). Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis showed that the genes related to GOT1 expression were mainly concentrated in “hematopoietic cell lineage” and “leukocyte transendothelial migration” signaling pathways. Collectively, GOT1 expression may be a useful prognostic indicator in AML, especially in patients who have undergone allo-HSCT.https://www.frontiersin.org/article/10.3389/fonc.2020.00379/fullacute myeloid leukemiaglutamate oxaloacetate transaminase 1chemotherapyallogeneic hematopoietic stem cell transplantationprognosis |